CADTH | Evidence Driven
CADTH | Evidence Driven

Search CADTH

Filters

No filters applied.

Showing 31 - 40 results of 3649

Download as CSV

Mirabegron (Myrbetriq) (Last Updated: Nov 27, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Myrbetriq
Manufacturer:
Astellas Pharma Canada Inc.
Submission Type:
Initial
Indications:

Bladder, overactive

Aflibercept (Eylea) (Last Updated: Nov 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Eylea
Manufacturer:
Bayer Canada Inc.
Submission Type:
Initial
Indications:

Macular degeneration, age-related

Adalimumab (Humira) (Last Updated: Dec 23, 2013)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Humira
Manufacturer:
AbbVie
Submission Type:
Initial
Indications:

Ulcerative colitis

OnabotulinumtoxinA (Botox) (Last Updated: Nov 25, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Botox
Manufacturer:
Allergan Inc.
Submission Type:
Initial
Indications:

Urinary incontinence

Ustekinumab (Stelara) (Last Updated: Oct 30, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Stelara
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Arthritis, Psoriatic

Sofosbuvir (Sovaldi) (Last Updated: Oct 1, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Sovaldi
Manufacturer:
Gilead Sciences Canada Inc.
Submission Type:
Initial
Indications:

Hepatitis C, chronic

Fluticasone furoate /vilanterol (Breo Ellipta) (Last Updated: Oct 29, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Breo Ellipta
Manufacturer:
GlaxoSmithKline
Submission Type:
Initial
Indications:

Chronic Obstructive Pulmonary Disease (COPD)

Aripiprazole (Abilify) (Last Updated: Oct 1, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Abilify
Manufacturer:
Bristol-Myers Squibb Canada
Submission Type:
Initial
Indications:

Depression, Major Depressive Disorder (MDD)

Alemtuzumab (Lemtrada) (Last Updated: Oct 1, 2013)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Lemtrada
Manufacturer:
Genzyme Canada, a Division of sanofi-aventis Canada Inc.
Submission Type:
Initial
Indications:

Multiple Sclerosis, relapsing

Dolutegravir (Tivicay) (Last Updated: Oct 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Tivicay
Manufacturer:
ViiV Healthcare ULC
Submission Type:
Initial
Indications:

HIV infection